Celyad Oncology Announces November 2020 Investor Conference Schedule
Celyad Oncology SA (Euronext & Nasdaq: CYAD) has announced its participation in three upcoming healthcare conferences in November 2020. The events are: Bryan, Garnier & Co. Virtual European Healthcare Conference on November 16, Jefferies Virtual London Healthcare Conference on November 17 at 2:55 p.m. ET, and SVB Leerink Oncology 1x1 Day on November 19. The company focuses on developing CAR T therapies for cancer, supported by the Walloon Region funding. Investors can find more details on Celyad's website.
- Participation in three notable healthcare conferences could enhance visibility and investor interest.
- Focus on CAR T therapy development aligns with current trends in innovative cancer treatments.
- The statement includes forward-looking risks related to the Phase 1 trial initiation and ongoing impacts of COVID-19.
MONT-SAINT-GUIBERT, Belgium, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in November 2020:
Bryan, Garnier & Co. Virtual European Healthcare Conference
Date: Monday, November 16, 2020
Jefferies Virtual London Healthcare Conference
Date: Tuesday, November 17, 2020
Time: 2:55 p.m. ET / 8:55 p.m. CET
Webcast: A live and archived webcast of the presentation will be available in the Events section of the Celyad Oncology website
SVB Leerink Oncology 1x1 Day
Date: Thursday, November 19, 2020
About Celyad Oncology
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.
Forward-Looking Statement
This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncology’s pipelines and financial condition, results of operation and business outlook. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the expected date of the Phase 1 trial initiation by year-end 2020, our development of additional shRNA-based allogenic candidates from our CYAD-200 series towards clinical trial, and the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
Investor and Media Contacts:
Sara Zelkovic
Communications & Investor Relations Director
Celyad Oncology
investors@celyad.com
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
Source: Celyad Oncology SA
FAQ
What conferences is Celyad Oncology participating in November 2020?
What is the focus of Celyad Oncology's research and development?
What is the stock symbol for Celyad Oncology?
What risks does Celyad Oncology highlight in their latest press release?
